PUBLISHER: The Business Research Company | PRODUCT CODE: 1957552
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957552
Organic pharmaceutical excipients are substances of natural origin that are used in pharmaceutical formulations together with active pharmaceutical ingredients (APIs). They are obtained from sources such as plants, animals, or microorganisms and are widely regarded as safe for use in pharmaceutical applications.
The primary types of organic pharmaceutical excipients include oleochemicals, carbohydrates, petrochemicals, proteins, and others. Oleochemicals are a class of chemicals derived from oils and fats and are used across a broad range of products, including soaps, detergents, cosmetics, lubricants, and biodiesel. In pharmaceutical formulations, they serve functions such as binding agents, coating agents, colorants, disintegrants, and others, and are applied in oral, topical, parenteral, and other formulations.
Tariffs have created both challenges and opportunities for the organic pharmaceutical excipients market by increasing costs for imported natural raw materials, specialty carbohydrates, and protein-based excipients used in pharmaceutical formulations. These impacts are most evident in oral and parenteral formulation segments and in regions such as Asia-Pacific and Europe that rely heavily on cross-border sourcing. However, tariffs are also encouraging manufacturers to localize production, strengthen domestic supply chains, and invest in sustainable sourcing, which is supporting long-term market resilience and innovation.
The organic pharmaceutical excipients market research report is one of a series of new reports from The Business Research Company that provides organic pharmaceutical excipients market statistics, including organic pharmaceutical excipients industry global market size, regional shares, competitors with a organic pharmaceutical excipients market share, detailed organic pharmaceutical excipients market segments, market trends and opportunities, and any further data you may need to thrive in the organic pharmaceutical excipients industry. This organic pharmaceutical excipients market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The organic pharmaceutical excipients market size has grown strongly in recent years. It will grow from $12.21 billion in 2025 to $13.28 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to growth of generic drug manufacturing, rising use of excipients in oral formulations, availability of natural raw materials, increasing pharmaceutical production capacity, historical preference for proven excipient safety profiles.
The organic pharmaceutical excipients market size is expected to see strong growth in the next few years. It will grow to $18.99 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to expansion of biopharmaceutical pipelines, rising demand for sustainable drug formulations, increasing focus on patient-centric formulations, advancements in excipient processing technologies, stricter regulations favoring non-toxic excipients. Major trends in the forecast period include growing preference for plant-based and naturally derived excipients, rising demand for clean-label and non-toxic pharmaceutical ingredients, increased adoption of organic excipients in oral solid dosage forms, expansion of functional excipients enhancing drug stability and bioavailability, rising regulatory support for naturally sourced pharmaceutical additives.
The growing demand for pharmaceutical drugs is expected to drive the expansion of the organic pharmaceutical excipients market in the coming years. Pharmaceutical drugs are scientifically formulated substances used to diagnose, treat, prevent, or manage diseases by interacting with specific biological pathways to restore or maintain normal physiological function. One of the main factors contributing to the rising demand for pharmaceutical drugs is the increasing prevalence of complex and chronic health conditions, which require ongoing therapeutic intervention and encourage the development of more advanced, targeted, and accessible treatment options to support long-term patient care. Organic pharmaceutical excipients play a vital role in supporting this demand by improving drug stability, delivery, and bioavailability, thereby enabling the effective formulation and performance of a broad range of modern medicines. For instance, in January 2024, according to the New Drug Therapy Approvals 2023 report published by the Center for Drug Evaluation and Research (CDER), a US-based division of the U.S. Food and Drug Administration (FDA), CDER approved 55 novel drugs in 2023, of which 20 (36%) were classified as first-in-class, compared with 37 novel drug approvals in 2022. Therefore, the increasing demand for pharmaceutical drugs is contributing to the growth of the organic pharmaceutical excipients market.
Major players in the organic pharmaceutical excipients market are concentrating on the development of innovative products, such as label-friendly excipient systems, to address evolving formulation requirements, improve product transparency, and support clean-label initiatives in health-focused consumer markets. A label-friendly excipient system refers to a formulation-support material derived from natural or organic sources that enables safe, stable, and effective drug or supplement production while aligning with consumer preferences for simple, recognizable, and non-synthetic ingredients. For example, in April 2023, Colorcon, a US-based pharmaceutical excipient supplier, introduced Nutracore, an innovative range of label-friendly excipients designed to meet the specific needs of nutraceutical and dietary supplement manufacturers. These excipients are produced using natural and organic materials to address the growing demand for clean-label solutions while maintaining optimal manufacturability and performance. Nutracore excipients allow manufacturers to meet consumer expectations for transparent labeling without compromising product quality or functionality.
In May 2025, Roquette, a France-based supplier of plant-based ingredients and pharmaceutical excipients, acquired IFF Pharma Solutions for an undisclosed amount. Through this acquisition, Roquette seeks to enhance its global pharmaceutical excipient capabilities by incorporating IFF Pharma Solutions' advanced drug-delivery technologies, thereby expanding its product portfolio and accelerating growth in high-value formulation markets. IFF Pharma Solutions is a US-based provider of pharmaceutical excipients, drug-delivery polymers, and specialized formulation technologies.
Major companies operating in the organic pharmaceutical excipients market are Roquette Freres SA, DuPont de Nemours Inc., Ashland Inc., Kerry Group plc, Evonik Industries AG, Croda International plc, Innophos Holdings Inc., Wacker Chemie AG, Merck KGaA, Colorcon Asia Private Limited, JRS PHARMA GMBH + CO KG, Cargill Incorporated, Ingredion Incorporated, Sensient Technologies Corporation, Lonza Group Ltd., DFE PHARMA INDIA PRIVATE LIMITED., Omya AG, Sigachi Industries Pvt. Ltd., Meggle AG, Archer Daniels Midland Company
North America was the largest region in the global organic pharmaceutical excipients market in 2025. The regions covered in the organic pharmaceutical excipients market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the organic pharmaceutical excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The organic pharmaceutical excipient market consists of sales of starch, cellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Organic Pharmaceutical Excipients Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses organic pharmaceutical excipients market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for organic pharmaceutical excipients ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The organic pharmaceutical excipients market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.